Calendar of Live Events

There are dozens of blood sugar formulations on the market working to different degrees to help protect the vascular system and bring down HGBa1c. While endothelial protection has been a strength of these formulations, the weakness has been in affecting the HGBA1c itself.

Although many cardiovascular disease risk factors are frequently discussed, for some reason ACE2 activity is not usually described. This is unfortunate because decreased ACE2 activity is a major cause of cardiovascular disease morbidity and mortality. Interestingly, the ACE2 receptor is the main entry point for infection with SARS CoV-2 virus. In this lecture Dr. Yousef Elyaman will review the RAAS with a special focus on ACE2. Moreover, he will describe some of the potential cardiovascular damage that may occur with COVID-19 disease (as it inactivates ACE2) and will share practical tips that may help improve endothelial function.

The entrance of phytocannabinoids into natural medicine has been a boon for patients who now have this hard-won relief available for their use. However, the introduction of phytocannabinoids has given rise to a plethora of new formulas, many of them from new companies. As a result, there are questions about the quality of phytocannabinoid formulas, how to identify the right blend, and how to ensure the intended actives are contained in the formula being prescribed.